J. Ryff

发表

Assays for antibodies to human interferon-alpha: the need for standardization.

H. Schellekens, P. H. van der Meide, J. Ryff, 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Treatment of chronic hepatitis C with interferon: how long should a lasting response last if a lasting response could last?

J. Ryff, 1997, Journal of viral hepatitis.

To treat or not to treat?: The judicious use of interferon-α-2a for the treatment of chronic hepatitis B

J. Ryff, 1993 .

Usefulness of interferon for treatment of hepatitis C.

J. Ryff, 1995, Journal of hepatology.

The fluctuations of hepatitis C virus RNA and IgM anti‐HCV (core) serum levels correlate with those of alanine aminotransferases during the hepatitis relapses of patients treated with interferon

F. Negro, G. Leandro, R. Bonino, 1995, Journal of viral hepatitis.

Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon‐alpha

V. Carreño, I. Castillo, J. Quiroga, 1992, Journal of medical virology.

Interferons and Interleukins

S. Pestka, J. Ryff, 2019, Pharmaceutical Biotechnology.

In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus

C. Bernard, H. Gaya, J. Klastersky, 1981, Antimicrobial Agents and Chemotherapy.

Double‐blind, randomized controlled trial of interleukin‐2 treatment of chronic hepatitis B

G. Fattovich, A. Alberti, G. Giustina, 1998, Journal of medical virology.

Comparative study of three doses of interferon‐α2a in chronic active hepatitis B

G. Dusheiko, G. Cooksley, H. Thomas, 1994 .

To treat or not to treat? The judicious use of interferon-alpha-2a for the treatment of chronic hepatitis B.

J. Ryff, 1993, Journal of hepatology.

Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group.

A. Lok, H. Thomas, G. Dusheiko, 1994, Journal of viral hepatitis.

Limited protective effect of rough mutant antisera in murine Escherichia coli bacteremia

S. Zinner, J. Ryff, M. Keating, 1982, Infection.

Immunogenicity of rDNA-derived pharmaceuticals.

Huub Schellekens, H. Schellekens, Jean-Charles Ryff, 2002, Trends in pharmacological sciences.

'Biogenerics': the off-patent biotech products.

Huub Schellekens, H. Schellekens, Jean-Charles Ryff, 2002, Trends in pharmacological sciences.

Clinical investigation of the immunogenicity of interferon-alpha 2a.

J C Ryff, J. Ryff, 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Treatment of chronic hepatitis D with interferon alfa-2a.

P. van Eyken, V. Desmet, P. Farci, 1994, The New England journal of medicine.

Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a.

F. Negro, G. Leandro, F. Bonino, 1994, Gastroenterology.